Designing biomedical devices

Prostate cancer remains one of the most prevalent malignancies among men worldwide. Current screening strategies based on prostate-specific antigen (PSA) testing suffer from limited specificity, particularly in distinguishing early-stage and clinically significant disease. Consequently, there is a critical need for novel, non-invasive, and highly specific molecular biomarkers to improve early diagnosis and patient stratification.

Circulating microRNAs (miRNAs) have emerged as promising diagnostic candidates due to their remarkable stability in body fluids and their disease-specific expression profiles. Among them, miR-141-3p has been strongly associated with prostate cancer progression, metastatic burden, and treatment response, positioning it as a clinically relevant biomarker for advanced and aggressive disease phenotypes.